- Home
- NTIP vs LSTA Comparison
NTIP vs LSTA Comparison
Compare NTIP & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- LSTA
- Stock Information
- Founded
- NTIP 1990
- LSTA 1980
- Country
- NTIP United States
- LSTA United States
- Employees
- NTIP N/A
- LSTA N/A
- Industry
- NTIP Multi-Sector Companies
- LSTA Misc Health and Biotechnology Services
- Sector
- NTIP Miscellaneous
- LSTA Health Care
- Exchange
- NTIP Nasdaq
- LSTA Nasdaq
- Market Cap
- NTIP 32.9M
- LSTA 31.2M
- IPO Year
- NTIP 1998
- LSTA N/A
- Fundamental
- Price
- NTIP $1.38
- LSTA $2.55
- Analyst Decision
- NTIP
- LSTA Strong Buy
- Analyst Count
- NTIP 0
- LSTA 1
- Target Price
- NTIP N/A
- LSTA $15.00
- AVG Volume (30 Days)
- NTIP 15.2K
- LSTA 24.3K
- Earning Date
- NTIP 03-07-2025
- LSTA 02-27-2025
- Dividend Yield
- NTIP 7.25%
- LSTA N/A
- EPS Growth
- NTIP N/A
- LSTA N/A
- EPS
- NTIP N/A
- LSTA N/A
- Revenue
- NTIP $1,881,000.00
- LSTA N/A
- Revenue This Year
- NTIP N/A
- LSTA N/A
- Revenue Next Year
- NTIP N/A
- LSTA N/A
- P/E Ratio
- NTIP N/A
- LSTA N/A
- Revenue Growth
- NTIP 129.39
- LSTA N/A
- 52 Week Low
- NTIP $1.22
- LSTA $2.19
- 52 Week High
- NTIP $2.25
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- NTIP 50.88
- LSTA 42.39
- Support Level
- NTIP $1.34
- LSTA $2.41
- Resistance Level
- NTIP $1.42
- LSTA $2.66
- Average True Range (ATR)
- NTIP 0.03
- LSTA 0.19
- MACD
- NTIP 0.00
- LSTA 0.01
- Stochastic Oscillator
- NTIP 50.00
- LSTA 42.06
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.